China Resources Pharmaceutical Group (03320) announced the 2025 financial results for China Resources Boya Bio-Pharmaceutical Group. The company achieved total operating revenue of approximately 2.059 billion yuan, representing a year-on-year increase of 18.69%. However, net profit attributable to shareholders of the listed company was about 113 million yuan, a decrease of 71.61% compared to the previous year. Basic earnings per share were 0.22 yuan. The board proposed a cash dividend distribution of 0.73 yuan per 10 shares (including tax).